Henry Fuchs, M.D.

Henry is currently the President of Worldwide Research and Development at BioMarin Pharmaceuticals Inc. (NASDAQ: BMRN), having previously served as the Executive Vice President and Chief Medical Officer from 2009 to 2016. He is a seasoned biotech drug development executive.

From 2005 to 2008, Henry was Executive Vice President and Chief Medical Officer of Onyx Pharmaceuticals (NASDAQ: ONXX), overseeing expanded development of the kinase inhibitor Nexavar* and other key development programs. Additionally, Henry served in multiple roles of increasing responsibility from 1996 to 2005 at Ardea Biosciences (NASDAQ: RDEA), as Vice President, Clinical Affairs, President and Chief Operating Officer, and Chief Executive Officer. From 1987 to 1996, Henry held various positions at Genentech where, among other responsibilities, he led the clinical program that resulted in the approval of Pulmozyme.* Henry was also responsible for the Phase III development program that led to the approval of Herceptin* to treat metastatic breast cancer.

Henry received his M.D. from George Washington University and his B.A. in biochemical sciences from Harvard University.

* Trademarks are property of their respective owners.

About Cookies on This Site

This website uses cookies. Essential and functional cookies are necessary for the proper functioning of this website and cannot be refused. Other cookies are used for statistical purposes and will only be placed if you agree to their placement. For further details on cookies, how we use cookies and how to modify your choices regarding cookies, please read our Cookies Policy.